ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronEye IconIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailMenu BurgerPositive ArrowIcon PrintIcon SearchSite TitleTitle ChevronIcon Twitter
Health Technology

Daiichi Sankyo Co., Ltd.

  • 6,995.00 JPY
  • -79.00
  • -1.12%
  • Japan
    Aug 23, 2019
  • Ticker
    TKS(4568)
  • Prev. close
    7,074
  • Market cap (JPY)
    5,015.55B
  • Market cap (USD)
    47,030.30M
  • Shares
    709.01M

Business Summary

Daiichi Sankyo Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical products. It operates through the following segments: Daiichi Sankyo Group and Ranbaxy Group. The Daiichi Sankyo Group segment comprises of Daiichi Sankyo Co., Ltd. and its subsidiaries. The Ranbaxy Group segment includes its core company, Ranbaxy Laboratories Ltd. Both group segments deal with business activities in prescription drugs and general pharmaceutical products. The company was founded on September 28, 2005 and is headquartered in Tokyo, Japan.

Financial Highlights

Mar 2019 JPYUSD
Revenue929,717M8,383.78M
Gross Profit565,112M5,095.93M
Operating income90,461M815.73M
Income before tax85,831M773.98M
Net income93,410M842.33M
EBITDA136,630M1,232.07M
Diluted EPS143.871.29
Dividends Per Share700.63
Total Assets2,088.05B18,864.80M
Total liabilities838,343M7,574.13M
Total equity1,249.64B11,290.07M
Operating cash flow92,033M829.91M
Currency in JPYCurrency in USD

Historical Data

 Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019
Revenue 919,372M 986,446M 955,124M 960,195M 929,717M
Gross Profit 596,285M 667,824M 605,751M 614,174M 565,112M
Operating income 126,524M 154,054M 127,875M 112,326M 90,461M
Income before tax 79,936M 122,388M 87,788M 81,021M 85,831M
Net income 46,762M 82,282M 53,466M 60,282M 93,410M
EBITDA 168,547M 198,360M 175,248M 159,006M 136,630M
Diluted EPS 456.62 119.11 79.44 91.10 143.87
Dividends Per Share 60 70 70 70 70
Total Assets 1,982.28B 1,900.52B 1,914.97B 1,897.75B 2,088.05B
Total liabilities 674,973M 666,507M 743,545M 764,709M 838,343M
Total equity 1,304.05B 1,231.40B 1,175.89B 1,132.98B 1,249.64B
Operating cash flow 142,775M 174,281M 136,234M 108,439M 92,033M
 Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019
Revenue 8,368.84M 8,214.61M 8,820.26M 8,663.48M 8,383.78M
Gross Profit 5,427.85M 5,561.29M 5,593.91M 5,541.46M 5,095.93M
Operating income 1,151.72M 1,282.88M 1,180.88M 1,013.47M 815.73M
Income before tax 727.64M 1,019.18M 810.69M 731.02M 773.98M
Net income 425.66M 685.20M 493.74M 543.90M 842.33M
EBITDA 1,534.24M 1,651.83M 1,618.35M 1,434.65M 1,232.07M
Diluted EPS 4.15 0.99 0.73 0.82 1.29
Dividends Per Share 0.54 0.58 0.64 0.63 0.63
Total Assets 16,529.38M 16,909.31M 17,185.48M 17,844.41M 18,864.80M
Total liabilities 5,628.29M 5,930.04M 6,672.75M 7,190.49M 7,574.13M
Total equity 10,873.93M 10,956.05M 10,552.78M 10,653.33M 11,290.07M
Operating cash flow 1,299.65M 1,451.32M 1,258.07M 978.40M 829.91M

Valuation Measures

Mar 2019
PER35.36
ROA4.68%
ROE7.84%
Operating margin9.72%
Profit margin10.04%

Key executives

  • Chairman & Chief Executive Officer: Joji Nakayama
  • President, COO & Representative Director: Sunao Manabe
  • CFO, Representative Director & Vice President: Toshiaki Sai
  • Senior Managing Executive Officer, Global Head-R&D: Junichi Koga
  • Executive Officer & Manager-Audit: Ryoichi Watanabe

Shareholders

  • Daiichi Sankyo Co., Ltd. (8.6%)
  • Capital Research & Management Co. (World Investors) (6.5%)
  • Nippon Life Insurance Co. (5.0%)
  • Capital Research & Management Co. (Global Investors) (4.3%)
  • Asset Management One Co., Ltd. (3.3%)
  • Nomura Asset Management Co., Ltd. (3.2%)
  • BlackRock Fund Advisors (2.6%)
  • The Vanguard Group, Inc. (2.3%)
  • Mizuho Bank Pension Fund (2.0%)
  • The Shizuoka Bank, Ltd. (1.6%)

Contact Details

  • Website:http://www.daiichisankyo.co.jp
  • Address: Daiichi Sankyo Head Office Bldg, A&B, 3-5-1 Nihonbashi-honcho, Tokyo, 103-8426, Japan
  • Phone: +81.3.6225.1111

Related Companies

  • Daiichi Sankyo Belgium SA
  • Daiichi Sankyo Restricted Stock Compensation Plan
  • Daiichi Sankyo Pharma, Inc.
  • Novare Co. Ltd.
  • Daiichi Sankyo Pharmaceutical (Shanghai) Co. Ltd.
  • Daiichi Sankyo Venezuela SA
  • Daiichi Sankyo (Schweiz) AG
  • Daiichi Sankyo Hong Kong Ltd.
  • Daiichi Forging Dalian Co. Ltd.
  • Daiichi Sankyo Pharmaceutical (Beijing) Co. Ltd.
  • Kitasato Daiichi Sankyo Vaccine Co., Ltd.
  • Daiichi Sankyo Pension Fund
  • Daiichi Sankyo Espha Co., Ltd.
  • Daiichi Sankyo (Thailand) Ltd.
  • Daiichi Sankyo Employee Stock Ownership Plan
  • Daiichi Sankyo (China) Holdings Co., Ltd.
  • Daiichi Sankyo Ireland Ltd.
  • Sankyo Pharma Nederland BV
  • Daiichi Sankyo Taiwan Ltd.
  • NV Sankyo Pharma Belgium SA
  • Daiichi Sankyo Portugal Lda.
  • Daiichi Sankyo Nederland BV
  • Daiichi Sankyo Logistics Co. Ltd.
  • Daiichi Sankyo Italia SpA
  • U3 Pharma GmbH
  • Daiichi Sankyo Deutschland GmbH
  • Basics GmbH
  • Ranbaxy Italia SpA
  • Ranbaxy Europe Ltd.
  • Daiichi Sankyo UK Ltd.

Competitors

  • AstraZeneca PLC
  • Glenmark Pharmaceuticals Limited
  • Hanmi Pharmaceutical Co., Ltd.
  • Assertio Therapeutics, Inc.
  • Pieris Pharmaceuticals, Inc.
  • Gemphire Therapeutics Inc.
  • Amphastar Pharmaceuticals Inc
  • Deciphera Pharmaceuticals, Inc.
  • MacroGenics, Inc.
  • DURECT Corporation
  • Collegium Pharmaceutical, Inc.
  • Zyla Life Sciences
  • Esperion Therapeutics, Inc.
  • Quantum Genomics
  • Agios Pharmaceuticals, Inc.
  • Stemline Therapeutics, Inc.
  • BioCryst Pharmaceuticals, Inc.
  • Cerenis Therapeutics Holding SA
  • PTC Therapeutics, Inc.
  • AMAG Pharmaceuticals, Inc.
  • Cyclacel Pharmaceuticals, Inc.
  • Trovagene, Inc.
  • Biocon Limited
  • BioDelivery Sciences International, Inc.
  • Constellation Pharmaceuticals, Inc.
  • Puma Biotechnology, Inc.
  • Aileron Therapeutics, Inc.
  • UMN Pharma, Inc.
  • Aptose Biosciences Inc.
  • Y-mAbs Therapeutics, Inc.
Last Updated on 23 Aug, 2019

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Get Unlimited access

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world
.

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends June 30th

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to the Nikkei Asian Review has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media